Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Clinical · Molecular biology

High-Sensitivity ctDNA Analysis Uncovers Relevant Signals Missed by NGS in Pancreatic Cancer

Summary

This prospective study evaluated the prognostic significance of KRAS-mutant circulating tumor DNA (ctDNA) in patients with localized pancreatic ductal adenocarcinoma (PDAC). Analyses compared detection by next-generation sequencing (NGS) and digital droplet PCR (ddPCR) at various stages of perioperative treatment. Results indicated that the more sensitive ddPCR detected KRAS-mutant ctDNA in a greater proportion of patients than NGS. Detection by either method was associated with shorter overall survival, with ddPCR providing superior prognostic discrimination by identifying additional patients with poor outcomes missed by NGS. Integrating both methods could enhance perioperative risk stratification.

Critical appraisal

Clinical. This prospective cohort study demonstrates that KRAS-mutant ctDNA detection is a significant prognostic biomarker in patients with localized PDAC. ddPCR, with its superior sensitivity, identified patients at risk of poor outcomes missed by NGS, thereby improving perioperative risk stratification. For instance, median OS was 26.9 months for patients detected only by ddPCR, compared to 40.7 months for those with no detection. These findings suggest that integrating ddPCR could justify clinical trials to tailor therapeutic strategies (e.g., intensification of neoadjuvant or adjuvant treatment) for high-risk patients. Clinical impact could be seen in the medium term (3-5 years) after validation.

Molecular biology. The primary discovery is that ddPCR is significantly more sensitive than NGS for detecting KRAS-mutant ctDNA in PDAC, identifying 64.9% of patients compared to 17.2% by NGS at diagnosis. This sensitivity difference is crucial for the analytical validity of the biomarker. The study utilizes blood samples (liquid biopsy) and targets specific KRAS mutations (G12D/V/R). ddPCR’s ability to detect low-level signals, missed by NGS, highlights its potential for better identification of at-risk patients. If validated, this approach could lead to the development of clinical tests combining both technologies for more precise monitoring and improved patient selection for therapeutic trials.

The summary and the appraisal were written by a language model from the title and abstract of the original article. A curator decided to publish it. Methodology